Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs

Details

• Alternative Title:
  Int J Tuberc Lung Dis
• Personal Author:
  Kurbatova, Ekaterina V. ; Cavanaugh, J. Sean ; Shah, N. Sarita ; Wright, Abigail ; Kim, HeeJin ; Metchock, Beverly ; Van Deun, Armand ; Barrera, Lucia ; Boulahbal, Fadila ; Richter, Elvira ; Martín-Casabona, Nuria ; Arias, Fabiola ; Zemanova, Ilona ; Drobniewski, Francis ; Silva, Anabela Santos ; Coulter, Christopher ; Lumb, Richard ; Cegielski, J. Peter
• Description:
  Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0.5-11.6%). RMP-resistant isolates that were INH-susceptible had significantly lower rates of resistance to other first- and second-line anti-tuberculosis drugs (except rifabutin) compared to multidrug-resistant isolates. RMP resistance is not always a good proxy for a presumptive diagnosis of multidrug-resistant TB, which has implications for use of molecular assays that identify only RMP resistance-associated DNA mutations.
• Subjects:
  Antitubercular Agents Article DNA Mutational Analysis Drug Resistance Drug Resistance, Bacterial Humans Isoniazid Microbial Sensitivity Tests Molecular Diagnostic Tests Mycobacterium Tuberculosis Retrospective Studies Rifampicin Resistance Rifampin Tuberculosis Tuberculosis, Multidrug-Resistant

  More +
• Source:
  Int J Tuberc Lung Dis. 16(3):355-357
• Pubmed ID:
  22640449
• Pubmed Central ID:
  PMC4593496
• Document Type:
  Journal Article
• Funding:
  CC999999/Intramural CDC HHS/United States
• Volume:
  16
• Issue:
  3
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:929793ca088822139f4d78e5db1028d5549eb31728b37deaa6285d029f556fbf
• Download URL:
  https://stacks.cdc.gov/view/cdc/34755/cdc_34755_DS1.pdf
• File Type:
  [PDF - 120.90 KB ]